Last updated on November 2019

A Phase III randomized, placebo-controlled, double-blind trial of Sorafenib plus Erlotinib vs. Sorafenib plus Placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC)


Other Details:

For more information, please contact:
844.229.3710 / 646.776.7532 (local)
Bayer@emergingmed.com

For Study Locations, Click Here



Find a site near you

Start Over

Research Center

Located In: Additional Locations, MN USA
  Connect »